HeartFlow/$HTFL

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About HeartFlow

HeartFlow Inc is a commercial-stage medical technology company that has pioneered the use of software and AI to deliver a non-invasive solution for diagnosing and managing coronary artery disease CAD. The company operates and manages its business as one reportable and operating segment, which is the business of non-invasive coronary artery disease detection solutions. Geographically, it operates in United States, United Kingdom, Japan, and Rest of Europe, of which it derives maximum revenue from United States.

Ticker

$HTFL
Sector
Health
Primary listing
NASDAQ

Employees

699
Headquarters
Mountain View, United States
Website
www.heartflow.com

HeartFlow Metrics

BasicAdvanced
$2.7B
-
-$6.75
-
-

What the Analysts think about HeartFlow

Analyst ratings (Buy, Hold, Sell) for HeartFlow stock.

Bulls say / Bears say

Heartflow’s revenue for the quarter ended March 31, 2025 rose to $37.2 million from $26.8 million a year earlier, a 38.9% increase year-over-year, showing strong top-line momentum (Reuters)
The company raised $316.7 million in its U.S. IPO with shares surging 47.4% on debut, bringing its valuation to $2.27 billion and illustrating strong investor confidence in its AI-focused cardiac diagnostics platform (Reuters)
A real-world NHS England study published in Nature Medicine involving over 90,000 patients found that the CCTA+Heartflow FFRCT pathway cut invasive coronary angiography by 7% and reduced unnecessary procedures by 16%, emphasizing significant clinical and economic value (GlobeNewswire)
Heartflow posted a net loss of $32.3 million for the quarter ended March 31, 2025, up from $20.9 million a year earlier, highlighting its ongoing unprofitability and ongoing risks of cash burn (Reuters)
The IPO valued the company at $1.54 billion based on trailing twelve-month revenue of $136 million (ending March 31, 2025), implying a valuation multiple above 11× and raising expectations for the company to maintain rapid growth (Renaissance Capital & Reuters)
Although EviCore gave its first coverage recommendation in July 2025, the guideline takes effect October 1, 2025 and requires each insurer to adopt it on their own schedule, adding uncertainty to the timing and scale of reimbursement revenue (GlobeNewswire)
Data summarised monthly by Lightyear AI. Last updated on 30 Aug 2025.

HeartFlow Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

HeartFlow Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-

HeartFlow News

AllArticlesVideos
Heartflow Stock Opens Nearly 50% Above IPO Price in Latest Hot Debut

Heartflow Stock Opens Nearly 50% Above IPO Price in Latest Hot Debut

Barrons1 month ago
Medtech firm Heartflow gains 47% in solid Nasdaq debut

Medtech firm Heartflow gains 47% in solid Nasdaq debut

Reuters1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $HTFL

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs